Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of l-thyroxine sodium in preparation of medicine for treating kidney injury caused by depleted uranium

A technology for thyroxine sodium and kidney injury, which is applied in the application field of L-thyroxine sodium, can solve the problems of high nephrotoxicity, water and electrolyte disturbance, and low gastrointestinal absorption rate affected by the pH of catechol compounds

Active Publication Date: 2021-06-22
ARMY MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of DU nephrotoxicity, at present, drugs are mainly used to promote excretion, such as sodium bicarbonate, catechol compounds, hydroxypyridone compounds, etc., but these methods have the following problems: sodium bicarbonate Can cause disturbance of water and electrolytes; catechol compounds are greatly affected by pH and have low gastrointestinal absorption rate; hydroxypyridone compounds have high nephrotoxicity, etc. Therefore, there is still a lack of safe and effective DU detoxification drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of l-thyroxine sodium in preparation of medicine for treating kidney injury caused by depleted uranium
  • Application of l-thyroxine sodium in preparation of medicine for treating kidney injury caused by depleted uranium
  • Application of l-thyroxine sodium in preparation of medicine for treating kidney injury caused by depleted uranium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Cell experiment

[0033] (1) Experimental method: RLE-6TN cells were inoculated in 96-well plates, 5000 cells / well, placed in a constant temperature incubator for 24 hours, and 125, 250, 375, 500, 625 , 750, 875, and 1000 nmol / L L-thyroxine sodium solutions, and set up a normal control group and a control group at the same time, a total of 10 groups. After incubation for 1 h in a constant temperature incubator, 500 umol DU was added to each well except the normal control group. After 24 h of incubation, CCK-8 was added. After 2 h of incubation, the OD value was detected at 450 nm using a microplate reader.

[0034] (2) Results

[0035] Test data:

[0036] Experimental results of L-thyroxine sodium treating DU damaged cells

[0037] NC C 125 250 375 500 625 750 875 1000 1.931 0.517 0.869 0.707 1.028 0.955 1.010 1.074 0.794 0.537 1.484 0.523 0.533 0.738 1.124 0.823 1.006 1.075 0.540 0.624 1.917 0.522 ...

Embodiment 2

[0040] Embodiment 2 Animal experiments

[0041] (1) Materials: Sprague Dawley male rats, body weight 200±20g, euthyrox (provided by Merck KGaA, Darmstadt), DU, ultrapure water.

[0042] (2) Instruments: syringes, gavage needles

[0043] (3) Drug preparation method: make Eumethalol into powder, weigh an appropriate amount, suspend Eumethalone with ultrapure water, and draw the suspension. When using, suspend the solution evenly, and absorb an appropriate amount (in the form of L-thyroid Calculation based on the content of plain sodium), add ultrapure water and mix well, and administer by gavage.

[0044](4) Experimental method: 30 Sprague Dawley male rats (body weight 200±20 g) were randomly divided into 5 groups, 6 rats / group, respectively normal group (NC), control group (C), 20 ug / kg treatment group, 40 ug / kg treatment group, and 80 ug / kg treatment group. The NC group received no treatment and was fed normally; the C group received intraperitoneal injection of DU 5 mg / kg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of L-thyroxine sodium in the preparation of a drug for treating kidney damage caused by depleted uranium (DU). The application can effectively treat the thyroid and kidney damage caused by DU, and is helpful for the situation of suffering from two kinds of damage at the same time. Under the condition of reducing medication, it provides a new way for the treatment of thyroid and kidney damage. The application also has the effect of being safe to use.

Description

technical field [0001] The invention relates to the application of L-thyroxine sodium, in particular to the application of L-thyroxine sodium in the preparation of medicine for treating kidney damage caused by depleted uranium. Background technique [0002] Depleted uranium (DU) is a substance mainly composed of uranium-238. Because DU has good penetrability and cheap raw materials, it is widely used in nuclear power plants, counterweights, radiation protection and military activities (such as armor materials and ammunition components). In the production and experiment process of DU, there may be irregular operations that may cause it to be released into the environment, enter the body through the respiratory tract, digestive tract or skin, and cause damage to the body. [0003] DU can emit α and β particles with high linear energy transfer, which has both radiotoxicity and heavy metal toxicity, and its biological effects are related to many factors such as exposure dose, d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/198A61P13/12
CPCA61K31/198A61P13/12
Inventor 郝玉徽李蓉万会敏冉永红卢丙慧刘晶高继宁贺莹娟高瑞粟永萍
Owner ARMY MEDICAL UNIV